Previous close | 65.43 |
Open | 64.85 |
Bid | 64.70 x 0 |
Ask | 68.00 x 0 |
Day's range | 64.85 - 68.30 |
52-week range | 8.40 - 68.35 |
Volume | |
Avg. volume | 172,814 |
Market cap | 2.301B |
Beta (5Y monthly) | 0.67 |
PE ratio (TTM) | 26.49 |
EPS (TTM) | 2.51 |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
PLANEGG/MUNICH, Germany, April 29, 2024--MorphoSys AG (FSE: MOR; NASDAQ: MOR) reports results for the first quarter of 2024.
Novartis (NVS) enters into a license deal with Arvinas, Inc. (ARVN) for the worldwide development and commercialization of cancer candidate ARV-766. Shares of ARVN rise on the news.
Novartis (NVS) is set to cut jobs by 680 in its development organization to reshape workforce.